« Previous Next » Urologic Oncology: Seminars and Original Investigations
Volume 26, Issue 3 , Pages 246-249 , May 2008

The predictive value of multi-targeted fluorescent in-situ hybridization in patients with history of bladder cancer

Received 11 January 2007 ,Revised 17 February 2007 ,Accepted 21 February 2007.

References

Skacel M, Fahmy M, Brainard JA, et al. Multi-target fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol. 2003;169:2101–2105
Halling KC, King W, Sokolova IA, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol. 2000;164:1768–1775
Bubendorf L, Grilli B, Sauter G, et al. Multi-probe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol. 2001;116:79–86
- MEDLINE
- CrossRef
Sarosdy MF, Schellhammer P, Bokinsky G, et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol. 2002;168:1950–1954
Friedrich MG, Toma MI, Hellstern A, et al. Comparison of multi-target fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer. BJU Int. 2003;91:911–914
Zellweger T, Benz G, Cathomas G, et al. Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer. Int J Cancer. 2006;119:1660–1665
- MEDLINE
- CrossRef
American Joint Committee on Cancer. Urinary bladder. In: AJCC Cancer Staging Manual. 6th ed.. New York: Springer; 2002;p. 335–340
Soloway MS, Bruck DS, Kim SS. Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol. 2003;170:438–441
Gofrit ON, Pode D, Lazar A, et al. Watchful waiting policy in recurrent Ta G1 bladder tumor. Eur Urol. 2006;49:303–306